A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs

Science Translational Medicine

Volumn 3, Issue 91, 2011, Pages

  Shen, Lin ^a   Rabi, S Alireza ^a   Sedaghat, Ahmad R ^a,c   Shan, Liang ^a   Lai, Jun ^a   Xing, Sifei ^a   Siliciano, Robert F ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG TARGETING; EMBRYO; HILL COEFFICIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INTERMOLECULAR COOPERATIVITY; LIFE CYCLE; MATHEMATICAL PARAMETERS; MOLECULAR INTERACTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS INHIBITION; BIOLOGICAL MODEL; DOSE RESPONSE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; PHENOTYPE; REPRODUCIBILITY; VIRION;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; HIV PROTEASE INHIBITORS; INTEGRASE INHIBITORS; MODELS, BIOLOGICAL; PHENOTYPE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; VIRION;

EID: 79960373686     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002304     Document Type: Article

References (36)

1. R. M. Gulick, J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, J. A. Chodakewitz, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739 (1997).
2. S.M.Hammer, K. E. Squires, M.D. Hughes, J.M.Grimes, L. M.Demeter, J. S. Currier, J. J. Eron Jr., J. E. Feinberg, H. H. Balfour Jr., L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337, 725-733 (1997).
3. A. S. Perelson, P. Essunger, Y. Cao, M. Vesanen, A. Hurley, K. Saksela, M. Markowitz, D. D. Ho, Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387, 188-191 (1997).
4. S. Staszewski, J. Morales-Ramirez, K. T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D. F. Labriola, D. Farina, D. J. Manion, N. M. Ruiz, Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341, 1865-1873 (1999).
5. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents, Washington, DC, 2011), pp. 1-166.
6. B. A. Larder, G. Darby, D. D. Richman, HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731-1734 (1989).
7. J. M. Coffin, HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483-489 (1995).
8. X. Wei, S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, G. M. Shaw, Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122 (1995).
9. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, M. Markowitz, Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126 (1995).
10. D. Wodarz, M. A. Nowak, Mathematical models of HIV pathogenesis and treatment. Bioessays 24, 1178-1187 (2002).
11. R. M. Ribeiro, S. Bonhoeffer, M. A. Nowak, The frequency of resistant mutant virus before antiviral therapy. AIDS 12, 461-465 (1998).
12. L. Shen, S. Peterson, A. R. Sedaghat, M. A. McMahon, M. Callender, H. Zhang, Y. Zhou, E. Pitt, K. S. Anderson, E. P. Acosta, R. F. Siliciano, Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14, 762-766 (2008).
13. A. V. Hill, The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40, iv-vii (1910).
14. N. H. G. Holford, L. B. Sheiner, Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6, 429-453 (1981).
15. T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
16. J. N. Weiss, The Hill equation revisited: Uses and misuses. FASEB J. 11, 835-841 (1997).
17. L. A. Kohlstaedt, J. Wang, J. M. Friedman, P. A. Rice, T. A. Steitz, Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
18. M. Miller, J. Schneider, B. K. Sathyanarayana, M. V. Toth, G. R. Marshall, L. Clawson, L. Selk, S. B. Kent, A. Wlodawer, Structure of complex of synthetic HIV-1 protease with a substratebased inhibitor at 2.3 Å resolution. Science 246, 1149-1152 (1989).
19. H. Mitsuya, K. Maeda, D. Das, A. K. Ghosh, Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. Adv. Pharmacol. 56, 169-197 (2008).
20. A. Hoffman, A. Goldberg, The relationship between receptor-effector unit heterogeneity and the shape of the concentration-effect profile: Pharmacodynamic implications. J. Pharmacokinet. Biopharm. 22, 449-468 (1994).
21. Z. Ambrose, J. G. Julias, P. L. Boyer, V. N. Kewalramani, S. H. Hughes, The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J. Virol. 80, 2578-2581 (2006).
22. X. Yang, S. Kurteva, X. Ren, S. Lee, J. Sodroski, Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J. Virol. 79, 12132-12147 (2005).
23. S. F. Le Grice, T. Naas, B. Wohlgensinger, O. Schatz, Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10, 3905-3911 (1991).
24. D. J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, M. D. Miller, Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-650 (2000).
25. J. R. Rosé, L. M. Babé, C. S. Craik, Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69, 2751-2758 (1995).
26. K. K. Pandey, S. Bera, J. Zahm, A. Vora, K. Stillmock, D. Hazuda, D. P. Grandgenett, Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate. J. Virol. 81, 12189-12199 (2007).
27. S. Hare, S. S. Gupta, E. Valkov, A. Engelman, P. Cherepanov, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464, 232-236 (2010).
28. J. A. Briggs, M. N. Simon, I. Gross, H. G. Kräusslich, S. D. Fuller, V. M. Vogt, M. C. Johnson, The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11, 672-675 (2004).
29. T. Jacks, M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, H. E. Varmus, Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331, 280-283 (1988).
30. S. C. Pettit, J. C. Clemente, J. A. Jeung, B. M. Dunn, A. H. Kaplan, Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J. Virol. 79, 10601-10607 (2005).
31. S. C. Pettit, L. E. Everitt, S. Choudhury, B. M. Dunn, A. H. Kaplan, Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78, 8477-8485 (2004).
32. B. Müller, M. Anders, H. Akiyama, S. Welsch, B. Glass, K. Nikovics, F. Clavel, H. M. Tervo, O. T. Keppler, H. G. Krausslich, HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284, 29692-29703 (2009).
33. E. Agneter, E. A. Singer, W. Sauermann, T. J. Feuerstein, The slope parameter of concentrationresponse curves used as a touchstone for the existence of spare receptors. Naunyn Schmiedebergs Arch. Pharmacol. 356, 283-292 (1997).
34. T. Castrignanò, F. Aluffi-Pentini, V. Parisi, A novel parameter to estimate the minimum number of bound ligands needed to activate an ion channel. J. Theor. Biol. 199, 97-103 (1999).
35. D. Michel, Cooperative equilibrium curves generated by ordered ligand binding to multi-site molecules. Biophys. Chem. 129, 284-288 (2007).
36. Acknowledgments: We thank the AIDS Research and Reference Reagent Program of the NIH and Merck for providing anti - HIV-1 drugs. We thank J. Liu, E. Freire, and X. Yu for helpful discussions. We thank J. Siliciano, J. Blankson, and C. Durand for helpful review of the manuscript. Funding: This work was supported by the U.S. NIH grant AI081600 and by the Howard Hughes Medical Institute. Author contributions: L. Shen and R.F.S. designed the experiments. L. Shen, J.L., and S.X. performed the experiments. L. Shen, S.A.R., A.R.S., L. Shan, and R.F.S. analyzed the data. All of the authors contributed to the manuscript preparation. Competing interests: The authors declare that they have no competing interests.